Treace Medical Concepts, Inc.
NASDAQ:TMCI · NASDAQ Global Select
+$0.08 today
Vol 1.39M · Avg 0.73M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:TMCI · Revenue to Net Income
Key Ratios
Analysis
$207.3M of revenue converted into -$61.0M of net income for the selected period. Gross margin is 79.7% and net margin is -30.6%, showing how much revenue survives after costs and taxes. EPS is $-0.97, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $212.7M +1.6% | $209.4M +11.9% | $187.1M +31.9% | $141.8M +50.2% | $94.4M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $42.9M +4.5% | $41.1M +16.8% | $35.2M +27.8% | $27.5M +63.0% | $16.9M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $169.8M +0.9% | $168.3M +10.7% | $151.9M +32.9% | $114.3M +47.4% | $77.5M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 79.8% -0.6pp | 80.4% -0.8pp | 81.2% +0.6pp | 80.6% -1.5pp | 82.1% | 9.8% | 28.9% | 38.3% |
| Research & Development | $20.3M -1.5% | $20.6M +33.3% | $15.4M +13.7% | $13.6M +33.1% | $10.2M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $203.6M +0.1% | $203.4M +8.2% | $187.9M +36.6% | $137.6M +64.1% | $83.8M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $223.9M -0.0% | $224.0M +10.1% | $203.4M +36.3% | $149.2M +58.6% | $94.0M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $10.5M +24.7% | $8.4M +57.3% | $5.4M +150.9% | $2.1M +211.4% | $685.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$43.2M -2.6% | -$42.1M -7.8% | -$39.0M -7.5% | -$36.3M -129.5% | -$15.8M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -20.3% -0.2pp | -20.1% +0.8pp | -20.8% +4.7pp | -25.6% -8.8pp | -16.7% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$54.2M +2.8% | -$55.7M -8.3% | -$51.4M -47.6% | -$34.8M -111.0% | -$16.5M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -25.5% +1.1pp | -26.6% +0.9pp | -27.5% -2.9pp | -24.6% -7.1pp | -17.5% | 16.6% | 24.1% | 22.0% |
| Interest Income | $2.8M -43.1% | $4.9M -27.5% | $6.7M +412.3% | $1.3M +7194.4% | $18.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $5.3M +1.2% | $5.3M +1.7% | $5.2M +17.5% | $4.4M +8.3% | $4.1M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$4.8M -8714.5% | -$55.0K -102.9% | $1.9M +123.8% | -$8.0M -97.2% | -$4.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$59.0M -5.8% | -$55.7M -12.6% | -$49.5M -15.7% | -$42.8M -108.3% | -$20.6M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -27.7% -1.1pp | -26.6% -0.2pp | -26.5% +3.7pp | -30.2% -8.4pp | -21.8% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$59.0M -5.8% | -$55.7M -12.6% | -$49.5M -15.7% | -$42.8M -108.3% | -$20.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | -27.7% -1.1pp | -26.6% -0.2pp | -26.5% +3.7pp | -30.2% -8.4pp | -21.8% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 -3.3% | -$1 -11.1% | -$1 -5.2% | -$1 -102.6% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 -3.3% | -$1 -11.1% | -$1 -5.2% | -$1 -102.6% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $63.3M +1.9% | $62.1M +2.1% | $60.9M +10.1% | $55.3M +2.0% | $54.2M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $63.3M +1.9% | $62.1M +2.1% | $60.9M +10.1% | $55.3M +2.0% | $54.2M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Enhabit, Inc.
EHAB
$706.91M
CeriBell, Inc.
NASDAQ:CBLL
$673.67M
Surmodics, Inc.
SRDX
$614.51M
Bioventus Inc.
NASDAQ:BVS
$592.46M
The Oncology Institute, Inc.
NASDAQ:TOI
$517.91M
OrthoPediatrics Corp.
NASDAQ:KIDS
$472.99M
Evolus, Inc.
NASDAQ:EOLS
$436.08M
Standard BioTools Inc.
NASDAQ:LAB
$325.96M
Semler Scientific, Inc.
SMLR
$310.75M
RxSight, Inc.
NASDAQ:RXST
$191.87M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does TMCI generate?
Treace Medical Concepts, Inc. (TMCI) reported $212.69M of revenue in fiscal 2025.
Is TMCI profitable?
Treace Medical Concepts, Inc. (TMCI) reported -$59,002,000.00 of net income, with a net margin of -27.7%.
Explore More
Continue the stock analysis
Jump to another research area for this company.